Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-139609

Published: 2020

Journal Articles

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

A. Samer Al-Homsi, MD, Sebastien Anguille, MD, Jason Brayer, PhDMD, Dries Deeren, MD PhD, Nathalie Meuleman, PhD MD, Gareth Morgan, MDPhDFRCP, Taiga Nishihori, MD, Panagiota A. Sotiropoulou, PhD, Laure Twyffels, PhD, Jennifer Bolsee, PhD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD, Frédéric F. Lehmann, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139516

Published: 2020

Journal Articles

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

A. Samer Al-Homsi, MD, Enkhtsetseg Purev, MD PhD, Philippe Lewalle, Maher Abdul-Hay, MD, Daniel A Pollyea, MD, Adriano Salaroli, MD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Fabian Borghese, Caroline Lonez, PhD, Nathalie Braun, Florence Renard, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3844.

https://doi.org/10.1182/blood-2019-128267

Published: 2019

Journal Articles

Post-Transplant Cyclophosphamide Overcomes Graft-Versus-Host Disease Aggravation Induced By Extended Administration of Proteasome Inhibitors

A. Samer Al-Homsi, MD, Austin Goodyke, Kelli Cole, MSN, Marlee Muilenburg, BSN, Michael McLane, Sarah Abdel-Mageed, Muneer H. Abidi, MD, Stephanie F. Williams, MD

Blood (2016) 128 (22): 4543.

https://doi.org/10.1182/blood.V128.22.4543.4543

Published: 2016

Journal Articles

Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study

A. Samer Al-Homsi, MD, Marlee Muilenburg, BSN, Kelli Cole, MSN, Muneer H. Abidi, MD, Stephanie F. Williams, MD

Blood (2016) 128 (22): 4635.

https://doi.org/10.1182/blood.V128.22.4635.4635

Published: 2016

Journal Articles

Ixazomib Impairs Dendritic Cell Function and T Cell Proliferation and Affects the Development of GvHD in a Schedule-Dependent Fashion

Yuxin Feng, PhD, Austin Goodyke, Marlee Muilenberg, BSN, RN, Kelli Cole, MSN, RN, Kathleen Cannady, DVM, Anding Shen, PhD, A. Samer Al-Homsi, MD

Blood (2015) 126 (23): 1881.

https://doi.org/10.1182/blood.V126.23.1881.1881

Published: 2015

Journal Articles

Post-Transplant Cyclophosphamide and Bortezomib Combination for Prevention of GvHD after Allogeneic Blood and Marrow Transplantation Is Feasible and Produces Favorable Outcomes

A. Samer Al-Homsi, MD, Tara S Roy, NP, Kelli Cole, RN, MSN, Marlee Bogema, RN, BSN, Stephanie F Williams, MD, Ulrich A. Duffner, MD, Aly Mageed, MD

Blood (2014) 124 (21): 3920.

https://doi.org/10.1182/blood.V124.21.3920.3920

Published: 2014

NARROW

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Post-Transplant Cyclophosphamide Overcomes Graft-Versus-Host Disease Aggravation Induced By Extended Administration of Proteasome Inhibitors

Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study

Ixazomib Impairs Dendritic Cell Function and T Cell Proliferation and Affects the Development of GvHD in a Schedule-Dependent Fashion

Post-Transplant Cyclophosphamide and Bortezomib Combination for Prevention of GvHD after Allogeneic Blood and Marrow Transplantation Is Feasible and Produces Favorable Outcomes

Email alerts

ASH Publications

American Society of Hematology

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Post-Transplant Cyclophosphamide Overcomes Graft-Versus-Host Disease Aggravation Induced By Extended Administration of Proteasome Inhibitors

Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study

Ixazomib Impairs Dendritic Cell Function and T Cell Proliferation and Affects the Development of GvHD in a Schedule-Dependent Fashion

Post-Transplant Cyclophosphamide and Bortezomib Combination for Prevention of GvHD after Allogeneic Blood and Marrow Transplantation Is Feasible and Produces Favorable Outcomes

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only